Survival in patients paced for high degree AV block has been demonstrated to be influenced by underlying cardiac disease in particular congestive heart failure. One previous study has suggested that dual chamber pacing may improve the vital prognosis for such patients. To investigate this, 74 patients treated with rate adaptive atrial synchronous (VDD) and 74 patients treated with VVI pacemakers for high degree AV block, were retrospectively studied for a mean of 5.4 years by life-table analysis. The two groups had an equal distribution of age, sex, date of pacemaker implantation, and concomitant cardiovascular diseases. Total mortality and estimated survival did not differ between the two groups. The estimated survival in the VDD group at 1, 3, and 5 years for patients without and with congestive heart failure was 94%, 86% and 78%, and 92%, 83% and 72%, respectively. In the VVI group the corresponding values were 95%, 90%, and 83% for patients without congestive heart failure and 82%, 64%, and 47% for those with congestive heart failure (P = 0.008). Compared to the expected survival rate of the general Swedish population, only the VVI group with congestive heart failure, had an excess mortality (P = 0.007). Patients with high degree AV block have a fairly normal vital prognosis irrespective of pacing mode. The prognosis for patients with congestive heart failure was negatively affected by VVI pacing. Thus, for patients with congestive heart failure the choice of pacing mode is of vital importance, whereas for patients without congestive heart failure, other factors such as feeling of well-being and exercise capacity should decide the final choice of pacing mode.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.